Alluvi, previously BI 4744, presents a significant advance in weight loss treatment. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in clinical studies, arguably exceeding https://bookmarkstumble.com/story24264371/alluvi-a-comprehensive-dive-into-retatrutide-s-potential